Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | GMNN | O75496 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 4/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brl-15,572 SCHEMBL7741355 | 0.87 | MEN1 (1.00) | KMT2AMEN1MAPTCYP1A2CYP3A4 | |
| Brl-15,572 SCHEMBL17978413 | 0.85 | MEN1 (1.00) | KMT2AMEN1MAPTCYP1A2CYP3A4 | |
| SCHEMBL15702624 | 0.85 | DRD4 (0.64) | KMT2AMEN1MAPTCYP1A2CYP3A4 | |
| SCHEMBL12781854 | 0.79 | ADRA2A (0.71) | KMT2AMAPTLMNANPSR1HTR1A | |
| SCHEMBL11622944 | 0.77 | MAPT (0.58) | KMT2AMAPTLMNAHTR1ADRD4 | |
| SCHEMBL11667975 | 0.77 | MEN1 (0.56) | KMT2AMEN1MAPTCYP1A2CYP3A4 | |
| SCHEMBL3738538 | 0.77 | MEN1 (0.56) | KMT2AMEN1MAPTCYP1A2CYP3A4 | |
| SCHEMBL11804032 | 0.76 | KCNH2 (0.61) | KMT2AMAPTLMNANPSR1HTR1A | |
| SCHEMBL1460309 | 0.75 | KMT2A (1.00) | KMT2AMEN1MAPTHTR1AADRA2A | |
| SCHEMBL16035226 | 0.74 | KCNH2 (0.52) | KMT2AMAPTHTR1ADRD4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028499-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-02-01 | — | — | US | claimed |
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| US-20230346750-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-11648237-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4043016-A1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | The Regents of the University of California (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-3261640-A1 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of The University of California (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138138-A1 | 5HT AGONISTS FOR TREATING DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | KMT2A 1929/4885MEN1 396/4885MAPT 3499/4885 |
| US-20230346750-A1 | 5HT AGONISTS FOR TREATING DISORDERS | HTR1A, HTR5A, HTR2A | KMT2A 1091/4885MEN1 901/4885MAPT 1758/4885 |
| US-11648237-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | KMT2A 1091/4885MEN1 901/4885MAPT 1758/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | KMT2A 1017/4885MEN1 951/4885MAPT 748/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | KMT2A 4040/4885MEN1 3935/4885MAPT 1403/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | KMT2A 1091/4885MEN1 901/4885MAPT 1758/4885 |
| US-20180028499-A1 | 5HT AGONISTS FOR TREATING DISORDERS | HTR1A, HTR5A, HTR2A | KMT2A 1091/4885MEN1 901/4885MAPT 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.